vrc-pbspla043-00-vp
Vaccineexperimental
Clinical trial activity
2 trials · 10 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2015 (NCT02562482)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Chikungunya virusImmunity, active
Chikungunya virus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vrc-pbspla043-00-vp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03110770 | Phase 2 | Mar 29, 2017 | FHI 360, Leidos, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), PPD, The EMMES Corporation |
| NCT02562482 | Phase 2 | Oct 1, 2015 | FHI 360, GHESKIO, Haiti, Leidos, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Puerto Rico Clinical and Translational Reserach Consortium, The EMMES Corporation, University Hospital Pointe-a-Pitre, Guadeloupe, University of the French West Indies and French Guiana |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| FHI 360 | Academic/Hospital | 2 | 0 | 1 | 2015 |
| Leidos | For profit | 2 | 0 | 1 | 2015 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 1 | 2015 |
| National Institutes of Health (NIH) | Government | 2 | 0 | 1 | 2015 |
| The EMMES Corporation | For profit | 2 | 0 | 1 | 2015 |
| GHESKIO, Haiti | Academic/Hospital | 1 | 0 | 1 | 2015 |
| PPD | For profit | 1 | 0 | 1 | 2017 |
| Puerto Rico Clinical and Translational Reserach Consortium | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University Hospital Pointe-a-Pitre, Guadeloupe | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of the French West Indies and French Guiana | Academic/Hospital | 1 | 0 | 1 | 2015 |
10 organizations
Page 1 / 1